Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2 - PubMed (original) (raw)
Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2
L M Webb et al. Eur J Immunol. 1996 Oct.
Abstract
Collagen type II-induced arthritis (CIA) is an experimental model of arthritis that has been successfully used to dissect the pathogenesis of human rheumatoid arthritis and to identify potential therapeutic targets. We have used this model to evaluate the role of T cell co-stimulation in both disease development and progression. T cell co-stimulation is provided by ligation of CD28 with either B7-1 or B7-2 present on antigen-presenting cells and can be prevented by a soluble form of CTLA-4 (CTLA-4Ig) which binds with high affinity to both B7-1 and B7-2. We found that administration of CTLA-4Ig at the time of immunization prevented the development of CIA and was associated with lack of lymphocyte expansion within the draining lymph node and failure to produce anti-collagen IgG1 or IgG2a antibodies. To determine which CD28 ligand plays a more dominant role in CIA, we treated mice with monoclonal antibodies (mAb) against either B7-1 or B7-2. Neither anti-B7-1 nor anti-B7-2 had any effect on the course of CIA when given alone, but resulted in reduced incidence and clinical scores when given together. Interestingly, when treatment was delayed until after the onset of clinical disease, both CTLA-4Ig or anti-B7-1 plus anti-B7-2 mAb still ameliorated disease. Effective treatment was associated with a reduction in interferon-gamma production by lymph node cells following stimulation in vitro, suggesting that Th1 responses were diminished. This study points to a critical role of CD28 co-stimulation in the development and perpetuation of CIA in DBA/1 mice. Interestingly, it demonstrates an active role for T cells in the later stages of this disease and implicates both B7-1 and B7-2-mediated co-stimulation in the pathogenesis of CIA.
Similar articles
- Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC, Pettersson U, Runström A, Andersson M, Michaëlsson E. Tellander AC, et al. J Autoimmun. 2001 Aug;17(1):39-50. doi: 10.1006/jaut.2001.0527. J Autoimmun. 2001. PMID: 11488636 - Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis.
Quattrocchi E, Dallman MJ, Feldmann M. Quattrocchi E, et al. Arthritis Rheum. 2000 Aug;43(8):1688-97. doi: 10.1002/1529-0131(200008)43:8<1688::AID-ANR4>3.0.CO;2-C. Arthritis Rheum. 2000. PMID: 10943858 - Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Blazar BR, et al. J Immunol. 1999 Jun 1;162(11):6368-77. J Immunol. 1999. PMID: 10352249 - Costimulation and its role in organ transplantation.
Bluestone JA. Bluestone JA. Clin Transplant. 1996 Feb;10(1 Pt 2):104-9. Clin Transplant. 1996. PMID: 8680045 Review. - The B7-CD28 superfamily.
Sharpe AH, Freeman GJ. Sharpe AH, et al. Nat Rev Immunol. 2002 Feb;2(2):116-26. doi: 10.1038/nri727. Nat Rev Immunol. 2002. PMID: 11910893 Review.
Cited by
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.
Song Y, Li J, Wu Y. Song Y, et al. Signal Transduct Target Ther. 2024 Oct 4;9(1):263. doi: 10.1038/s41392-024-01952-8. Signal Transduct Target Ther. 2024. PMID: 39362875 Free PMC article. Review. - A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis.
Jiang FY, Zhang YZ, Tai YH, Chou CY, Hsieh YC, Chang YC, Huang HC, Li ZQ, Hsieh YC, Chen IJ, Huang BC, Su YC, Lin WW, Lin HC, Chao JI, Yuan SF, Wang YM, Cheng TL, Tzou SC. Jiang FY, et al. Inflamm Regen. 2023 Feb 16;43(1):13. doi: 10.1186/s41232-023-00264-8. Inflamm Regen. 2023. PMID: 36797799 Free PMC article. - Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.
Orvain C, Cauvet A, Prudent A, Guignabert C, Thuillet R, Ottaviani M, Tu L, Duhalde F, Nicco C, Batteux F, Avouac J, Wang N, Seaberg MA, Dillon SR, Allanore Y. Orvain C, et al. Arthritis Res Ther. 2022 Jan 5;24(1):13. doi: 10.1186/s13075-021-02709-2. Arthritis Res Ther. 2022. PMID: 34986869 Free PMC article. - HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
Rigby W, Buckner JH, Louis Bridges S Jr, Nys M, Gao S, Polinsky M, Ray N, Bykerk V. Rigby W, et al. Arthritis Res Ther. 2021 Sep 18;23(1):245. doi: 10.1186/s13075-021-02607-7. Arthritis Res Ther. 2021. PMID: 34537057 Free PMC article. Clinical Trial. - Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression.
Gao C, Gardner D, Theobalds MC, Hitchcock S, Deutsch H, Amuzie C, Cesaroni M, Sargsyan D, Rao TS, Malaviya R. Gao C, et al. Clin Exp Immunol. 2021 Dec;206(3):422-438. doi: 10.1111/cei.13659. Epub 2021 Sep 22. Clin Exp Immunol. 2021. PMID: 34487545 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical